ICU antibiotic dosing under the microscope: new study aims to get it right
NCT ID NCT07167524
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 21 times
Summary
This study looks at how the antibiotic piperacillin-tazobactam is cleared from the body by continuous kidney replacement therapy in intensive care patients with severe infections. Researchers will measure drug levels in 24 adults to help doctors give the right dose—avoiding underdosing (which can lead to treatment failure) and overdosing (which can cause side effects). The goal is to improve antibiotic dosing for critically ill patients on kidney machines.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Rouen Hospital
Rouen, 76031, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.